The central challenge in cardiac electrophysiology is that heart cells communicate through rapidly propagating electrical waves. In a healthy heart, a precisely timed wave of depolarization sweeps across the muscle, triggering coordinated contraction. In diseased tissue, these waves can fragment, circle back on themselves, or originate from ectopic sites, producing arrhythmias that range from benign to lethal. Conventional interventions, from antiarrhythmic drugs to implanted pacemakers and ablation catheters, act on slow timescales or with coarse spatial resolution. What has been missing is a tool that can both observe and modulate cardiac electrical activity at the scale of individual cells, on millisecond timescales, within a continuous feedback loop.

The new work addresses this gap by exploiting optogenetics, a technique in which light-sensitive proteins borrowed from microbes are expressed in target cells. When blue light strikes channelrhodopsin, a light-gated ion channel embedded in the cell membrane, the channel opens and positive ions flow inward, depolarizing the cell and triggering an action potential. By genetically engineering human induced pluripotent stem cell-derived cardiomyocytes to express such opsins, researchers gain a remote, genetically specified actuator: any region of the cellular network can be electrically stimulated simply by illuminating it, with no physical contact required.

Stimulation alone, however, is only half of the control problem. The other half is sensing. The system pairs optogenetic actuation with optical voltage imaging, using fluorescent indicators whose emission changes with membrane potential. High-speed cameras capture the fluorescence of the cardiomyocyte network frame by frame, allowing the researchers to reconstruct the electrical state of the tissue in real time: which cells are resting, which are firing, and how excitation waves are propagating across the culture. This optical readout replaces the electrode arrays traditionally used to map cardiac activity, eliminating the invasiveness, wiring complexity, and spatial limitations of contact-based sensing.

The truly novel element is the holographic light engine that ties sensing and actuation together. Rather than illuminating the culture with a uniform beam or scanning a single laser spot, the researchers use a spatial light modulator to shape light into arbitrary two-dimensional patterns, projected onto the cell layer through holographic principles. A computer-generated hologram determines, pixel by pixel, where light intensity is delivered. This means the system can stimulate a single cell, a stripe of tissue, a curved wavefront mimicking the sinus node, or multiple disconnected regions simultaneously, all with subcellular spatial resolution and microsecond-scale temporal precision. The hologram can be updated faster than the dynamics of a cardiac action potential, which is essential for genuine real-time control.

Closing the loop requires software that can translate what the cameras see into what the light projector should do next. The control algorithm continuously monitors the optical voltage signals, compares the observed electrical behavior against a desired target state, and computes the illumination pattern needed to drive the network toward that state. If an excitation wave propagates too slowly, the system can deliver light pulses ahead of the wavefront to accelerate it. If an unwanted wave appears in the wrong location, the system can suppress it or redirect it. If the goal is a specific pacing frequency, the controller adjusts the timing and geometry of optical stimuli on every beat, compensating for the natural variability of biological tissue. This is the defining feature of closed-loop control: the intervention is not preprogrammed but continuously recalculated from live measurements.

The researchers demonstrated that this architecture can reliably entrain human cardiomyocyte networks to desired pacing patterns, guiding the rhythm of electrically active tissue that would otherwise beat at its own intrinsic rate. Beyond simple pacing, the holographic system’s spatial freedom enables more sophisticated interventions, such as shaping the direction and curvature of propagating waves or confining activity to defined regions of the network. Such capabilities are directly relevant to the study of arrhythmia mechanisms, where reentrant waves, spiral waves, and conduction blocks are the underlying culprits. A tool that can create, steer, and terminate such waves on demand in human-derived tissue provides an unprecedented experimental platform for arrhythmia research.

The significance for drug development and precision medicine is considerable. Human induced pluripotent stem cell-derived cardiomyocytes already allow pharmaceutical researchers to test compounds on human heart cells rather than animal tissue, but standard assays capture only bulk behavior, such as average beat rate or field potential duration. A closed-loop optical system adds an active dimension: it can probe how a tissue responds to perturbation, measure its vulnerability to arrhythmia induction, and quantify the effects of drugs on conduction velocity, refractory periods, and wave dynamics under precisely controlled stimulation conditions. In principle, patient-specific cell lines could be engineered with opsins and screened not just for passive responses but for behavior under stress, revealing proarrhythmic risks that conventional tests miss.

Looking further ahead, the all-optical nature of the approach suggests possibilities beyond the laboratory dish. Because neither sensing nor actuation requires physical contact, the conceptual framework is compatible with future cardiac therapies in which light delivered through optical fibers or implanted micro-LEDs could pace or resynchronize heart tissue in a feedback-controlled manner, guided by optical or electrical sensors. Such light-based pacemakers could adapt their stimulation pattern beat by beat, something conventional devices, which deliver fixed electrical pulses on fixed schedules, cannot do. Significant hurdles remain before any clinical translation, including delivering opsins safely to adult human myocardium, achieving sufficient light penetration in thick tissue, and ensuring long-term stability of both the genetic and optical components. The current study is confined to engineered cell networks in vitro, and the authors’ achievement should be understood as a foundational demonstration of control methodology rather than a therapy.

Even within that scope, the work marks a conceptual milestone. It shows that a living, electrically excitable human tissue can be observed, modeled, and steered in real time by a machine that touches nothing, intervening only through shaped light. The convergence of optogenetics, holographic projection, fast fluorescence imaging, and feedback control points toward a broader paradigm in synthetic biology and bioelectronic medicine: organs and organoids treated not as passive specimens but as dynamic systems that can be regulated the way engineers regulate any other process. For cardiac science, where rhythm is everything, the ability to write rhythm into human heart tissue with light, and to correct it when it goes wrong, may reshape how arrhythmias are studied, how drugs are validated, and, eventually, how failing electrical systems in the heart are repaired.

Subject of Research: All-optical closed-loop control of human cardiomyocyte networks using holographic optogenetics

Article Title: All-optical closed-loop control of human cardiomyocyte networks exploiting holographic optogenetics

Article References: Wendland, R., Schmieder, F., Sikandar, M. A., Knüppel, F. P., Zimmermann, W.-H., Bergmann, O., Büttner, L., & Czarske, J. W. (2026). All-optical closed-loop control of human cardiomyocyte networks exploiting holographic optogenetics. Communications Engineering, 5(1), Article 159. https://doi.org/10.1038/s44172-026-00779-1

Image Credits: AI Generated

DOI: 10.1038/s44172-026-00779-1

Keywords: holographic optogenetics, cardiomyocytes, closed-loop control, cardiac electrophysiology, optical voltage imaging, arrhythmia, induced pluripotent stem cells, channelrhodopsin, spatial light modulator, cardiac tissue engineering, bioelectronic medicine, optogenetic pacing

The central idea behind the study is neuromodulation, the deliberate adjustment of nerve activity to change the function of an organ. For the heart, the relevant nerves belong to the autonomic nervous system, the network that operates largely outside conscious control. Sympathetic branches act like an accelerator, speeding the heart when the body demands more oxygen, while parasympathetic branches act as a brake, slowing it during rest and recovery. Clinicians have long known that adjusting this balance can treat rhythm disorders, but the tools available to do so have been crude, invasive, or both. Focused ultrasound offers a way to deliver energy to a precisely defined volume of tissue deep inside the body, stimulating or suppressing neural structures without any incision.

Ultrasound neuromodulation has attracted growing interest over the past decade because sound waves interact with tissue in ways that electrodes cannot. An ultrasound transducer can focus acoustic energy at a target millimeters across, several centimeters beneath the skin, while leaving intervening tissue essentially untouched. The mechanical and thermal effects of the focused beam can alter the excitability of nerve fibers, changing how likely they are to fire action potentials. Depending on the acoustic parameters chosen, the same technology can excite or inhibit neural activity, giving researchers a reversible dial for nervous system function rather than a simple on-off switch.

What distinguishes the new work is the emphasis on image guidance. Delivering energy to the region around the heart is technically demanding because the target moves constantly with each heartbeat and shifts with every breath. The researchers integrated their ultrasound system with imaging that allowed them to track and compensate for this motion, keeping the acoustic focus locked on the intended neural target as the body moved. This kind of closed-loop control is widely regarded as essential if ultrasound neuromodulation is ever to leave the laboratory, because even small targeting errors could disperse the acoustic energy to unintended structures or miss the nerve tissue altogether.

The reported outcome is that this image-guided stimulation could regulate heart rate. By directing focused ultrasound at cardiac neural targets, the team demonstrated that the technique could influence the pace of the heartbeat in a controlled fashion, adjusting the balance between the nerves that accelerate the heart and those that slow it. Regulation, rather than simple stimulation, is the crucial claim. A clinically useful therapy would need to raise or lower heart rate on demand, or damp pathological overactivity, and the study presents its approach as capable of that kind of bidirectional control.

The technical machinery required for this achievement is considerable. High-intensity focused ultrasound systems of the kind used for ablating tumors deliver enough energy to destroy tissue, but neuromodulation typically operates at far lower intensities, below thresholds that would cause lasting damage. The acoustic parameters, including frequency, pulse duration, and repetition rate, determine whether the beam primarily excites nerve fibers, suppresses them, or produces transient heating that changes their behavior. Finding parameter sets that reliably modulate cardiac nerves without harming the surrounding myocardium is one of the field’s central challenges, and the published work contributes data toward that goal.

Why does this matter for medicine? Disturbances of heart rate and rhythm are among the most common and lethal problems in clinical cardiology. Abnormally fast rhythms, abnormally slow rhythms, and chaotic fibrillation all arise from malfunctions in the heart’s electrical control system, and the autonomic nerves that supply the heart are deeply implicated in many of these conditions. Catheter ablation, in which a physician threads wires into the heart and burns small areas of tissue, is effective for some disorders but is invasive and carries procedural risk. Drugs can modulate autonomic tone but act throughout the body, producing side effects far from the heart. A noninvasive, focal, and reversible method for adjusting cardiac nerve activity would fill a genuine gap in the therapeutic arsenal.

The study also speaks to a broader trend in bioelectronic medicine, a field built on the idea that many diseases can be treated by adjusting the electrical signals carried by nerves rather than by delivering chemicals. Researchers have implanted electrodes on the vagus nerve to treat epilepsy and inflammatory conditions, and others have explored stimulation of the carotid sinus and spinal cord for cardiovascular indications. Ultrasound offers these same possibilities from outside the body, which would eliminate implantation surgery and infection risk. The heart, with its well-mapped autonomic innervation and its easily monitored output, is a natural proving ground for the concept, because heart rate itself provides an immediate, continuous readout of whether the neuromodulation is working.

As with any early-stage study, important questions remain before patients could benefit. The durability of the effect, the precise neural structures targeted, the safety margins for repeated sessions, and the translation of results across species are all matters that will require further investigation. The team’s own account presents the work as a demonstration of feasibility: that image guidance can keep a focused ultrasound beam on a moving cardiac target, and that the resulting neuromodulation is sufficient to regulate heart rate. Scaling from demonstration to therapy will demand larger and longer studies, refinement of the targeting algorithms, and careful assessment of any off-target effects on neighboring tissue.

Nevertheless, the publication marks a noteworthy step for a technology that many researchers hope will reshape how medicine interacts with the nervous system. The combination of focused ultrasound with real-time imaging transforms neuromodulation from a procedure requiring precision hardware implanted inside the body into something closer to an examination: the patient lies still, the imaging system tracks the target, and the acoustic beam delivers its influence without a single incision. If subsequent studies confirm and extend these results, the day may come when clinicians tune the heart’s rhythm the way this study did, with sound alone, guided by images, and reversed the moment the therapy ends.

The physics underlying this approach rewards a closer look, because it explains both the promise and the difficulty of the method. Ultrasound waves at the megahertz frequencies typically used for neuromodulation travel through soft tissue at roughly fifteen hundred meters per second and can be steered by phasing the emissions of hundreds of individual elements on a transducer array. Each element fires with a slightly different delay, so that the wavefronts arrive simultaneously at a chosen point, constructive interference concentrates the acoustic pressure there, and tissue elsewhere receives comparatively little energy. This electronic steering means the focus can be repositioned in milliseconds purely by changing the timing signals, a property that pairs naturally with the fast feedback demanded by a beating heart.

The choice of neural target is equally consequential. The heart’s autonomic control is organized around ganglionated plexi, clusters of neurons embedded in the epicardial fat pads near the pulmonary veins, the superior vena cava, and the atria. These microganglia act as local integration centers, relaying and processing signals from the vagus nerve and the sympathetic chain before they reach the cardiac conduction system. Cardiac surgeons and electrophysiologists have known for decades that disturbing these clusters alters atrial rhythm tendencies, which is precisely why they represent attractive targets for noninvasive modulation. Delivering acoustic energy to such small structures, however, requires submillimeter accuracy sustained over many cardiac cycles.

Motion compensation of this kind borrows heavily from techniques developed in radiation oncology, where tumor-tracking linear accelerators adjust beam delivery to a patient’s respiratory cycle. The cardiac problem is harder still, because the heart moves faster than the lungs and exhibits beat-to-beat variability. A successful tracking system must therefore anticipate where the target will be when each acoustic pulse arrives, rather than simply following its past position, and any latency in the imaging chain must be accounted for in the control algorithm.

Safety considerations extend beyond the avoidance of thermal injury. Regulatory frameworks for medical ultrasound, built around indices that estimate heating and the potential for cavitation, will need to be interpreted carefully for a therapy whose intended effect is functional rather than destructive. Repeated exposure of the same neural tissue raises questions about cumulative changes in nerve excitability, and the possibility that acoustic energy scattered by ribs or lung tissue could stimulate unintended structures deserves systematic study. The chest wall itself presents an acoustic obstacle, since bone reflects and absorbs ultrasound strongly, so coupling of the beam through an intercostal window is a practical constraint on positioning.

The experimental logic of using heart rate as an endpoint also deserves emphasis. Unlike modulation of deeper brain circuits, where effects must be inferred indirectly, cardiac neuromodulation produces a continuous, quantitative, beat-by-beat readout that can be captured with noninvasive electrocardiography. This tight feedback loop makes the heart an ideal model system for validating the principles of image-guided acoustic neuromodulation generally, and lessons learned here may well inform applications to the peripheral and central nervous system, where comparable targeting and monitoring challenges await solutions.

Subject of Research: Noninvasive image-guided focused ultrasound neuromodulation of cardiac autonomic nerves to regulate heart rate

Article Title: Image-guided cardiac focused ultrasound neuromodulation regulates heart rate

Article References: Piao, X., Wei, Y., Yao, X., Xu, Z., Pan, J.-J., Hu, P., & Cheng, B. (2026). Image-guided cardiac focused ultrasound neuromodulation regulates heart rate. Communications Engineering. https://doi.org/10.1038/s44172-026-00774-6

Image Credits: AI Generated

DOI: 10.1038/s44172-026-00774-6

Keywords: focused ultrasound, neuromodulation, heart rate, autonomic nervous system, image guidance, cardiology, bioelectronic medicine, ultrasound therapy, cardiac nerves, noninvasive stimulation, Image-guided, cardiac

In a groundbreaking study led by Imanuel Lerman and his team at the UC San Diego Qualcomm Institute, researchers have painted an ambitious picture for the future of bioelectronic medicine. This comprehensive literature review serves as a strategic roadmap for the field, confirming its rising prominence in both diagnosis and treatment. The insights derived from this extensive research, bolstered by 180 references to provide solid grounding, aim to encourage fellow scientists and healthcare professionals to explore this transformative potential further.

One of the key breakthroughs highlighted by Lerman and his colleagues is the emergence of non-invasive bioelectronic techniques. Unlike traditional surgical implants, these methods minimize risk while providing significant advantages over conventional drug therapies. With an emphasis on scalable solutions, this unique approach ensures that treatment does not necessitate complex logistics with drug storage—most devices only require a power source. Moreover, bioelectronic devices can leverage the body’s inherent mechanisms, using electrical signals to modulate inflammation without the side effects associated with pharmaceuticals.

The implications of non-invasive bioelectronic devices are particularly significant in the creation of "closed-loop" systems that promise to revolutionize healthcare. By utilizing sensors that continuously monitor an individual’s physiological condition, these devices can tailor treatment regimens in real-time, adjusting dosages according to actionable biomarker feedback. This individualization presents a formidable advance over traditional pharmacotherapy, which typically prescribes a uniform dose for all patients, regardless of their specific biological responses.

Such high levels of adaptability are rare in medical treatments today, yet bioelectronic medicine is primed to redefine this dynamic. With non-invasive neuromodulation techniques gaining wider acceptance, we stand on the brink of a new era where therapies could profoundly alter the treatment landscape for conditions as diverse as depression, chronic pain, and movement disorders.

The possibilities for diagnostics within the domain of bioelectronic medicine are equally tantalizing. The research team argues that each infectious agent prompts a distinct physiological response over time, potentially allowing healthcare professionals to create an extensive pathogen library. Such a database would not only assist in diagnosing diseases but could also form the basis for targeted neuromodulation treatments designed to mitigate the symptoms linked to various infections, thereby expediting recovery processes.

Of particular interest is the recognition that mental health disorders are closely tied to inflammatory processes and the immune response. Various conditions including post-traumatic stress disorder and generalized anxiety disorder can be deeply intertwined with disruptions to the autonomic nervous system. Lerman’s study highlights how bioelectronic medicine can address these issues by monitoring neuroinflammatory responses to assess mental health intensity and deploying tailored treatments accordingly.

A breakthrough methodology potentially set to usher in this new approach is autonomic neurography (ANG). This technique empowers researchers to gather precise data on how the autonomic nervous system operates under different conditions, which can yield critical insights into mental health vulnerabilities. By capturing such data in clinical trials, clinicians can apply a precision medicine framework that aligns specific interventions with a patient’s unique symptom profile.

The advancements in bioelectronic medicine aren’t just the result of academic inquiry; they have garnered support from several high-profile agencies, including the U.S. Defense Advanced Research Projects Agency and the National Institutes of Health. These entities recognize the importance of strategic investment in research initiatives that can yield high-impact results, emphasizing the need for focused efforts to bring the innovations of bioelectronic medicine from the lab to real-world applications.

Despite the promising trajectory, Lerman emphasizes that there’s still substantial work ahead. Many bioelectronic strategies are in their infancy, requiring extensive validation through clinical trials before they can become commonplace in treatment paradigms. Researchers must address numerous challenges around technology integration, medical device regulation, and patients’ varying responses to neuromodulation.

Looking to the immediate future, the publication of this pivotal research will undoubtedly stir dialogue among scientists, healthcare providers, and policymakers. As the conversation expands, increased interdisciplinary collaborations could yield a wealth of innovations, tipping the scale toward a healthcare model defined by prevention, early diagnosis, and customized treatment plans based on a patient’s individual physiology.

While the applications of bioelectronic medicine are burgeoning, there is also a profound sense of hope associated with these advances. By harnessing insights from physiology, neuroscience, and engineering, we may be closing in on medical solutions that not only alleviate symptoms but tackle the underlying causes of diseases with unprecedented precision. As bioelectronic medicine continues to evolve, we are poised on the threshold of a transformative era in healthcare.

Subject of Research:
Article Title: Next Generation Bioelectronic Medicine: Making the Case for Non-Invasive Closed Loop Autonomic Neuromodulation
News Publication Date: 21-Jan-2025
Web References: Bioelectronic Medicine
References: N/A
Image Credits: Credit: Courtesy of the Qualcomm Institute, UC San Diego

Keywords: Bioelectronics, biomedical technologies, neuromodulation, personalized medicine, non-invasive techniques, inflammation, mental health.